Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC

Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC | Lung Cancer Dispatch | Scoop.it

"A large phase III study investigating necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as first-line treatment for advanced squamous non–small cell lung cancer show a statistically significant improvement in overall survival of patients with stage IV disease.


"Patients receiving necitumumab plus chemotherapy had a median survival of 11.5 months compared to 9.9 months for patients treated with chemotherapy alone.


"Progression-free survival and disease control rate were also significantly improved."


Editor's note: This story is about a clinical trial that is testing the effectiveness of a new treatment for lung cancer patients. So far, the trial has found that the treatment is promising for people with stage IV squamous non-small cell lung cancer (NSCLC). To learn more about clinical trials, and the risks and advantages for patients who participate in them, click here.

Cancer Commons's insight:

The ASCO Post  |  May 16, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Chemotherapy-Tarceva Combination May Be Effective for Some Lung Cancer Patients

Chemotherapy-Tarceva Combination May Be Effective for Some Lung Cancer Patients | Lung Cancer Dispatch | Scoop.it

Results from the FASTACT clinical trial suggest that interspersing erlotinib (Tarceva) among rounds of chemotherapy improves outcomes in non-small cell lung cancer (NSCLC). Patients with advanced NSCLC received six cycles of gemcitabine (Gemzar) plus carboplatin (Paraplatin) or cisplatin (Platinol), with Tarceva added during the second half of each chemotherapy cycle. This regimen prolonged time without cancer worsening and increased survival compared to patients who had received chemotherapy and placebo, though the benefit was only seen in patients with mutations in the EGFR gene. This approach may be most useful for patients whose EGFR status is unknown, as patients with known EGFR mutations may be even better served by first-line treatment with Tarceva alone.

Cancer Commons's insight:

Healio | Jul 10, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

EGFR Antibody Increases Survival in Lung Cancer Trial

EGFR Antibody Increases Survival in Lung Cancer Trial | Lung Cancer Dispatch | Scoop.it

The new cancer drug necitumumab increased survival in the SQUIRE clinical trial, a phase III trial examining squamous non-small cell lung cancer (NSCLC).  Patients with stage IV squamous NSCLC who received necitumumab in addition to the chemotherapy agents cisplatin (Platinol) and gemcitabine (Gemzar) survived longer than those treated with chemotherapy alone. Necitumumab is an antibody (a type of immune system protein) that blocks the function of EGFR, a protein that plays an important role in the survival, spread, and blood supply of tumors.

Cancer Commons's insight:

Wall Street Journal | Aug 13, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

VeriStrat Status Predicts Responsiveness to Tarceva Treatment in Elderly Lung Cancer Patients

VeriStrat® is a blood test for advanced non-small cell lung cancer (NSCLC) patients intended to determine whether the patients would benefit from erlotinib (Tarceva) treatment. A retrospective analysis of blood samples from elderly patients (age 70+ years) with advanced NSCLC who had been treated with either Tarceva, gemcitabine (Gemzar), or both found that patients with a "good" VeriStrat result had better outcomes than those with a "poor" result when given Tarceva either alone or in combination with Gemzar; the benefits of Gemzar alone were unaffected by VeriStrat status. The study authors conclude that elderly patients with "poor" VeriStrat results should be treated with Gemzar, while first-line Tarceva treatment may be appropriate for patients with "good" Veristrat results.

Cancer Commons's insight:

Journal of Thoracic Oncology | Jan 30, 2013

more...
No comment yet.